Loading...

Purified anti-human CD4 Antibody

Pricing & Availability
Clone
RPA-T4 (See other available formats)
Regulatory Status
RUO
Workshop
IV T114
Other Names
T4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
RPA-T4_Purified_060507
Human peripheral blood lymphocytes stained with purified RPA-T4, followed by anti-mouse IgGs FITC
  • RPA-T4_Purified_060507
    Human peripheral blood lymphocytes stained with purified RPA-T4, followed by anti-mouse IgGs FITC
Compare all formats
Cat # Size Price Save
300501 25 µg ¥5,280
300502 100 µg ¥8,580
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules, and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
Activ, Block, IHC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The RPA-T4 antibody binds to the D1 domain of CD4 (CDR1 and CDR3 epitopes) and can block HIV gp120 binding and inhibit syncytia formation. Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections3,4,5, blocking of T cell activation1,2, and spatial biology (IBEX)10,11.  This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300569 - 300574).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. (Activ)
  2. Moir S, et al. 1999. J. Virol. 73:7972. (Activ)
  3. Deng MC, et al. 1995. Circulation 91:1647. (IHC)
  4. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  5. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  6. Lan RY, et al. 2006. Hepatology 43:729.
  7. Zenaro E, et al. 2009. J. Leukoc. Biol. 86:1393. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Liu J, et al. 2018. Cell Physiol Biochem. 45:1034. PubMed
  2. Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed
  3. Shahine A, et al. 2019. Nat Commun. 10:56. PubMed
  4. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  5. Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed
  6. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  7. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
  8. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  9. Meckiff BJ, et al. 2019. J Immunol. 203:1276. PubMed
  10. Ivan Jelcic et al. 2018. Cell. 175(1):85-100 . PubMed
  11. Alroqi F, et al. 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed
  12. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  13. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  14. Campbell GR, et al. 2021. Theranostics. 11:9009. PubMed
  15. Chakhtoura M, et al. 2021. PLoS Pathog. 17:e1009732. PubMed
  16. Mo Y, et al. 2021. STAR Protocols. 2(2):100453. PubMed
  17. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  18. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  19. Yoshihara S, et al. 2019. Front Immunol. 0.545833333. PubMed
  20. Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed
  21. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
  22. Yang R, et al. 2020. Cell. 183(7):1826-1847.e31. PubMed
  23. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  24. Gañán-Gómez I, et al. 2022. Nat Med. . PubMed
  25. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  26. Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed
  27. Cosgrove PR, et al. 2021. Pediatr Res. . PubMed
  28. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  29. Peng T, et al. 2021. Front Immunol. 12:735643. PubMed
  30. Jeyanathan M, et al. 2022. JCI Insight. 7:. PubMed
  31. Zhao J, et al. 2017. Sci Immunol. 2:eaan5400. PubMed
  32. Jakob M, et al. 2020. Cells. 10:. PubMed
  33. Gee MH, et al. 2018. Cell. 172:549. PubMed
  34. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  35. Henrick BM, et al. 2021. Cell. . PubMed
  36. Roussel M, et al. 2021. Cell Reports Medicine. 2(6):100291. PubMed
  37. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  38. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  39. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  40. Schwabenland M, et al. 2021. Immunity. . PubMed
  41. Senosain MF, et al. 2021. Sci Rep. 11:14424. PubMed
  42. Ford ES, et al. 2021. J Clin Invest. 131:. PubMed
  43. Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed
  44. Sutherland APR, et al. 2019. Sci Rep. 9:15302. PubMed
  45. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  46. Lavaert M, et al. 2020. Frontiers in Immunology. 1.610416667. PubMed
  47. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  48. Ainai A, et al. 2020. Microbiol Immunol. 64:313. PubMed
  49. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  50. Olety B, et al. 2021. Sci Adv. 7:eabj7398. PubMed
  51. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
RRID
AB_314069 (BioLegend Cat. No. 300501)
AB_314069 (BioLegend Cat. No. 300502)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Dendritic cells, Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD4 RPA-T4 FC
Biotin anti-human CD4 RPA-T4 FC
FITC anti-human CD4 RPA-T4 FC,SB
PE anti-human CD4 RPA-T4 FC
PE/Cyanine5 anti-human CD4 RPA-T4 FC
PE/Cyanine7 anti-human CD4 RPA-T4 FC
Purified anti-human CD4 RPA-T4 FC,CyTOF®,Activ,Block,IHC
APC/Cyanine7 anti-human CD4 RPA-T4 FC
Alexa Fluor® 488 anti-human CD4 RPA-T4 FC,ICC
Alexa Fluor® 647 anti-human CD4 RPA-T4 FC,SB
Pacific Blue™ anti-human CD4 RPA-T4 FC
Brilliant Violet 421™ anti-human CD4 RPA-T4 FC,ICC
Alexa Fluor® 700 anti-human CD4 RPA-T4 FC,SB
PerCP anti-human CD4 RPA-T4 FC
PerCP/Cyanine5.5 anti-human CD4 RPA-T4 FC
Brilliant Violet 570™ anti-human CD4 RPA-T4 FC
Brilliant Violet 650™ anti-human CD4 RPA-T4 FC
Purified anti-human CD4 (Maxpar® Ready) RPA-T4 FC,CyTOF®
Alexa Fluor® 594 anti-human CD4 RPA-T4 FC,ICC
Brilliant Violet 510™ anti-human CD4 RPA-T4 FC
PE/Dazzle™ 594 anti-human CD4 RPA-T4 FC
Brilliant Violet 785™ anti-human CD4 RPA-T4 FC
Brilliant Violet 605™ anti-human CD4 RPA-T4 FC
Brilliant Violet 711™ anti-human CD4 RPA-T4 FC
APC/Fire™ 750 anti-human CD4 RPA-T4 FC
CD4 Fluorophore Sampler Kit RPA-T4 FC
CD4 Fluorophore Sampler Kit with Veri-Cells™ PBMC RPA-T4 FC
TotalSeq™-A0072 anti-human CD4 RPA-T4 PG
TotalSeq™-B0072 anti-human CD4 RPA-T4 PG
TotalSeq™-C0072 anti-human CD4 RPA-T4 PG
Ultra-LEAF™ Purified anti-human CD4 RPA-T4 FC,CyTOF®,Activ,Block,IHC
TotalSeq™-D0072 anti-human CD4 RPA-T4 PG
Go To Top Version: 5    Revision Date: 08/23/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account